Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2019 Oct 8;19(2):397–408. doi: 10.1158/1535-7163.MCT-19-0319

Figure 1:

Figure 1:

MPNST cells are sensitive to glutamine deprivation and competitive glutamine antagonists. A) Live cell counts from trypan blue exclusion assay comparing growth of human MPNST cells (sNF96.2) in control (>2mM glutamine) or low (50μM) glutamine media normalized to number of cells seeded. Cells were counted every 24 hours for five days. Data is +/− S.D. B) Percent growth of cells based on alamar blue fluorescence (590 nm) of human MPNST or immortalized Schwann cells (ipn02.32λ; imm SC) growing in glutamine-free media with added glutamine titrated at increasing concentrations. Viability was measured at 72 hours glutamine treatment. Data is +/− S.D. C) Structures of DON and JHU395 with clogP values indicated. D) Percent viable MPNST and immortalized Schwann cells based on alamar blue fluorescence normalized to untreated controls following treatment with DON or JHU395. Viability was measured at 72 hours drug treatment. Data is +/− S.D. *** 0.0001 < p ≤ 0.001, ** 0.001 < p ≤ 0.01, * 0.01 < p ≤ 0.05 by Student’s t-test (A).